Logo1

Mirzaev KB., Rytkin E., Ryzhikova KA., Grishina EA., Sozaeva ZhA., Fedorinov DS., Konova OD., Giliarov MIu., Belyakova GA., Andreev DA., Sychev DA. The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes. Drug Metabolism and Personalized Therapy 2018.

 

DOI: https://doi.org/10.1515/dmpt-2018-0006

скачать материал

Просмотров: 8955

Zastrozhin MS, Grishina EA, Denisenko NP, Skryabin VY, Markov DD, Savchenko LM, Bryun EA, Sychev DA. Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. Pharmacogenomics and Personalized Medicine 2018:11;113—119.

DOI https://doi.org/10.2147/PGPM.S160763

скачать материал

 

Просмотров: 8937

Fedorinov DS, Mirzaev KB, Ivashchenko DV, Temirbulatov II, Sychev DA, Maksimova NR, Chertovskih JV, Popova NV, Tayurskaya KS, Rudykh ZA. Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia). Drug Metab Pers Ther. 2018 May 8.
 
doi: 10.1515/dmpt-2018-0004.
 
 
Просмотров: 8270

Denisenko NP, Sychev DA, Sizova ZM, Smirnov VV, Ryzhikova KA, Sozaeva ZA, Grishina EA. CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole. 2018:11;107—112.

Просмотров: 8398

Sychev DA, Ashraf GM, Svistunov AA, Maksimov ML, Tarasov VV, Chubarev VN, Otdelenov VA, Denisenko NP, Barreto GE, Aliev G. The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo. Drug Design, Development and Therapy. 2018:12;1147—1156.

DOI https://doi.org/10.2147/DDDT.S149069

 

скачать материал

 

Просмотров: 8428
  1. Ivashchenko DV, Rudik AV, Poloznikov AA, et al. Which cytochrome P450 metabolizes phenazepam? Step by step in silico, in vitro, and in vivo studies. Drug Metab Pers Ther. 2018 May 4.
  2. Kryukov AV, Sychev DA, Andreev DA, et al. Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. Pharmacogenomics and Personalized Medicine. 2018,11:43—49
  3. Sychev DA, Vardanyan A, Rozhkov A, et al. CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis. Genet Test Mol Biomarkers. 2018 Jan;22(1):51-54.
  4. Zastrozhin MS, Grishina EA, Ryzhikova KA, et al. The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction. Pharmacogenomics and Personalized Medicine 2018,11:1—5.